Figure 5From: Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's diseaseIncorporation of PPI-1011 in retinal DHA and DHA-containing ethanolamine plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn) 24 hours after the last dose of a 14 day treatment with once daily dosing of 10 or 50 mg/kg in gelatin capsules. Groups consisted of 6 rabbits.Back to article page